JNJ Johnson & Johnson

+1.18  (+1%)
Previous Close 135.42
Open 135.29
Price To Book 5.67
Market Cap 366358190565
Shares 2,681,977,969
Volume 5,160,272
Short Ratio 1.45
Av. Daily Volume 10,267,861

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Phase 3 discontinuation announced October 17, 2017.
Acute myeloid leukemia (AML)
Approval announced February 14, 2018.
Non-metastatic castration-resistant prostate cancer (CRPC)
FDA Approval announced July 17, 2018.
Approval announced August 2, 2017.
Second-line Chronic graft-versus-host disease (GVHD)
Approval announced October 30, 2017. sNDA flled December 14, 2018.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
FDA Approval announced October 30, 2018.
Type 2 diabetes
Phase 3 trial stopped early due to positive efficacy - July 16, 2018.
Diabetic Kidney Disease
Approval announced May 7, 2018.
DARZALEX (Daratumumab) - ALCYONE
Frontline multiple myeloma (non-transplant)
PDUFA estimate March 3, 2019 assuming priority review. FDA Advisory Committee Meeting February 12, 2019 voted 14-2 that benefits outweigh risks.
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Marginal zone lymphoma
Approval announced October 13, 2017.
Plaque psoriasis
Approval announced October 20, 2017.
Psoriatic arthritis (PsA)
Approval announced October 20, 2017.
Ankylosing Spondylitis
Approval announced July 13, 2017.
Plaque psoriasis
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
Rheumatoid arthritis
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
sNDA approval announced February 8, 2018.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
NDA filed 3Q 2018.
Urothelial cancer
Announced May 18, 2018 that dosing will be stopped.
Alzheimer’s disease
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Phase 2/3 trial initiation announced July 11, 2018.
Guselkumab (GALAXI 1)
Crohn's disease
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 2 trial initiation announced November 19, 2018.
Guselkumab (NOVA)
Hidradenitis Suppurativa
Phase 3 data at ASH 2018 noted HR 0.56 (44% reduction of progression/death) - OS not mature.
Daratumumab - MAIA
Newly Diagnosed Multiple Myeloma (NDMM)
Phase 3 data due early 2019.
Guselkumab vs Cosentyx - ECLIPSE
Phase 2a initiation announced January 17, 2019.
Ulcerative colitis
sBLA filed December 20, 2018.
Ulcerative colitis
Phase 3 data met co-primary endpoints - January 30, 2019.
Metastatic castration-sensitive prostate cancer (mCSPC).
Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.
Niraparib (Galahad)
Castration-Resistant Prostate Cancer

Latest News

  1. What's in the Cards for Perrigo (PRGO) This Earnings Season?
  2. J&J Left to Fend for Itself in Talc Suits After Supplier’s Bankruptcy
  3. [$$] The SEC’s Misguided Attack on Shareholder Arbitration
  4. J&J Baby Powders: Feds Dig Into Claims Of Cancer-Causing Asbestos
  5. Dow Tumbles on Weaker-Than-Expected Economic Data, Nike Loses Its Footing
  6. The Midday Rundown: February 21, 2019
  7. Trading Johnson & Johnson Stock Amid Federal Subpoenas
  8. US STOCKS-Weak economic data, healthcare shares pull Wall St lower
  9. Stock Market News: Nike, J&J Face Potential Product Problems
  10. Johnson & Johnson receives federal subpoenas related to baby powder litigation
  11. US STOCKS-Wall St dragged down by healthcare stocks, weak economic data
  12. Stock Losses Deepen; These Two Dow Jones Stocks Falter
  13. The Latest From Johnson & Johnson's Asbestos Scandal
  14. Johnson & Johnson's stock falls to lead Dow losers after being subpoenaed by DOJ, SEC
  15. Stocks Open Lower As 2 Dow Jones Names Stumble
  16. Why Is Johnson & Johnson (JNJ) Up 5.9% Since Last Earnings Report?
  17. US STOCKS- Wall St set to open lower after economic data
  18. US STOCKS-Futures flat as U.S.-China talks progress
  19. Nike, Lyft, J&J, Kraft Heinz and Trade Deal Progress - 5 Things You Must Know
  20. Stocks making the biggest moves premarket: Hormel, Apple, Nike, Domino's Pizza & more